No headlines found.
Business Wire (Wed, 17-Dec 8:15 AM ET)
Kairos Pharma Provides Shareholder Update
Business Wire (Tue, 4-Nov 8:00 AM ET)
Business Wire (Mon, 20-Oct 8:00 AM ET)
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Kairos Pharma Ltd. trades on the AMEX stock market under the symbol KAPA.
As of January 16, 2026, KAPA stock price declined to $0.87 with 44,225 million shares trading.
KAPA has a beta of 0.23, meaning it tends to be less sensitive to market movements. KAPA has a correlation of 0.00 to the broad based SPY ETF.
KAPA has a market cap of $18.17 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that KAPA belongs to (by Net Assets): VXF.
KAPA has underperformed the market in the last year with a return of -50.7%, while the SPY ETF gained +18.1%. In the last 3 month period, KAPA fell short of the market, returning -25.4%, while SPY returned +5.0%. However, in the most recent 2 weeks KAPA has outperformed the stock market by returning +19.6%, while SPY returned +1.2%.
KAPA support price is $.84 and resistance is $.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KAPA shares will trade within this expected range on the day.
